Testicular germ cell tumours (TGCTs) are the most common cancer in men between the ages of 15 and 40 years. Luckily, the majority of these patients can expect to be cured. However, the optimal follow-up for patients after their initial management is still subject to debate. During a keynote lecture at the 2021 annual BMUC meeting, Prof Robert Huddart discussed some of the key aspects of this follow-up process.